<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963859</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0441</org_study_id>
    <nct_id>NCT00963859</nct_id>
  </id_info>
  <brief_title>Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder</brief_title>
  <official_title>Phase II Evaluation of Robotic-assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to evaluate how many lymph nodes are left behind
      after robotic-assisted removal and are then found after a wider incision is made, in patients
      who are having their bladder removed for the treatment of bladder cancer.

      The primary objective is to compare the lymph node yield achieved by performing a
      robotic-assisted laparoscopic extended pelvic lymph node dissection (RA-PLND) compared to a
      second-look open lymph node dissection (O-PLND) among patients undergoing radical cystectomy
      for transitional cell carcinoma of the bladder.

      The secondary objectives will be to collect prospective outcomes data related to the
      performance of RA-PLND and robotic-assisted cystectomy (RA-C) including operative times,
      estimated blood loss, transfusions, complications, return to diet, utilization of pain
      medication, hospital length, return to regular activities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Background:

      Research has shown that the more lymph nodes removed as part of a radical cystectomy (bladder
      removal) for invasive bladder cancer, the better. However, the number of lymph nodes removed
      varies from person to person. The standard surgical techniques such as robot-assisted
      procedures are new, and researchers want to be able to more reliably tell if the specific
      number of lymph nodes removed is enough to be considered a &quot;complete&quot; removal.

      In this study, researchers will remove the required lymph nodes using a standard
      robotic-assisted procedure, and then remove any additional lymph nodes that remain and need
      to be removed, using a wider (&quot;open&quot;) incision in the abdomen. This open technique is also
      being done for standard of care. It is needed in order to complete the &quot;urinary diversion&quot;
      part of the surgery (a procedure of surgically making way for urine to pass out of the body
      so that it does not go through the bladder).

      The main goal of the study is to see if the robotic-assisted procedure removes all of the
      required lymph nodes. The open technique will allow researchers to evaluate how many lymph
      nodes were left behind after robotic-assisted removal.

      It is possible that the machine may have problems and not be available for use on the
      scheduled day of surgery. If that happens, you will have the option to reschedule surgery or
      have standard open surgery. It is also possible that the machine could have problems during
      your surgery. If that happens, your doctor will continue with standard open surgery. Your
      study doctor will discuss these possible situations with you.

      You will be asked to sign a separate consent form for these surgical procedures, which will
      describe the procedures and their risks in more detail.

      Follow-up:

      You will be asked to fill out a brief pain survey once a week for 7 weeks after surgery. The
      survey will take about 5 minutes to complete. You will also be given a diary to record your
      daily pain medication use. It will also take about 5 minutes to complete. You will continue
      to complete the questionnaire once a week and to fill out the diary daily for 6 weeks.

      End-of-Study Visit:

      You will visit the clinic 6-12 weeks after surgery for an end-of-study visit. You will have a
      chest x-ray. Your pain medication use and pain level surveys will be collected. After this
      visit, you will be off-study.

      This is an investigational study. The robotic-assisted bladder removal is FDA approved for
      this purpose. Up to 60 patients will be enrolled in this study. All will be enrolled at The
      University of Texas (UT) MD Anderson Cancer Center (MDACC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved</measure>
    <time_frame>3 months including surgery and post-operative period.</time_frame>
    <description>The median yield (the lymph node count) allows for comparison of how many lymph nodes are left behind after robotic-assisted removal and are then found after a wider incision is made. Specifically a robot-assisted laparoscopic extended pelvic lymph node dissection (RA-PLND) is compared to a second-look open lymph node dissection (O-PLND) among participants undergoing radical cystectomy for urothelial carcinoma of the bladder. The median yield lymph nodes illustrate the adequacy of extended pelvic lymph node dissection using a robotic-assisted technique, i.e. whether the robotic-assisted laparoscopic radical cystectomy yields a sufficient number of lymph nodes to be oncologically equivalent to the open procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Percentage Median Yield</measure>
    <time_frame>3 months including surgery and post-operative period.</time_frame>
    <description>The median yield (the lymph node count) allows for comparison of how many lymph nodes are left behind after robotic-assisted removal and are then found after a wider incision is made. Specifically a robot-assisted laparoscopic extended pelvic lymph node dissection (RA-PLND) is compared to a second-look open lymph node dissection (O-PLND) among participants undergoing radical cystectomy for urothelial carcinoma of the bladder. The median yield lymph nodes illustrates the adequacy of extended pelvic lymph node dissection using a robotic-assisted technique.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Robotic-assisted laparoscopic surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Robotic-assisted laparoscopic extended pelvic lymph node dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic-assisted laparoscopic surgery</intervention_name>
    <description>During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.</description>
    <arm_group_label>Robotic-assisted laparoscopic surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are eligible for a radical cystectomy and who, in the opinion of the
             treating MDACC physician, are candidates for a robotic-assisted laparoscopic technique
             for management of the bladder and lymph nodes.

          2. Diagnosis of transitional cell carcinoma of the bladder.

          3. Medical fitness for open radical cystectomy by consensus of MDACC urology and
             anesthesia faculty (medicine/cardiology clearance by common best practice criteria).

          4. Staging inclusion by cystoscopic biopsy and bimanual examination under anesthesia:
             carcinoma in-situ, T1, T2.

        Exclusion Criteria:

          1. Prior pelvic radiation.

          2. Morbid obesity, i.e., body mass index (BMI)&gt; 35.

          3. Metastatic disease, bulky disease--T3a/b, prostatic stromal invasion.

          4. Non-transitional cell histology.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W. Davis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <results_reference>
    <citation>Davis JW, Gaston K, Anderson R, Dinney CP, Grossman HB, Munsell MF, Kamat AM. Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol. 2011 Jan;185(1):79-83. doi: 10.1016/j.juro.2010.09.031. Epub 2010 Nov 12.</citation>
    <PMID>21074799</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2009</study_first_submitted>
  <study_first_submitted_qc>August 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <results_first_submitted>June 28, 2012</results_first_submitted>
  <results_first_submitted_qc>April 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2013</results_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Robotic-assisted laparoscopic surgery</keyword>
  <keyword>Extended pelvic lymph node dissection</keyword>
  <keyword>RA-PLND</keyword>
  <keyword>Second-look open lymph node dissection</keyword>
  <keyword>O-PLND</keyword>
  <keyword>Radical Cystectomy</keyword>
  <keyword>Urinary diversion</keyword>
  <keyword>Bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: October 10, 2007 to December 07, 2009; All recruitment done in a medical clinic setting.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Robotic-assisted Laparoscopic Surgery</title>
          <description>Robotic-assisted laparoscopic extended pelvic lymph node dissection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Robotic-assisted Laparoscopic Surgery</title>
          <description>Robotic-assisted laparoscopic extended pelvic lymph node dissection</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="40" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved</title>
        <description>The median yield (the lymph node count) allows for comparison of how many lymph nodes are left behind after robotic-assisted removal and are then found after a wider incision is made. Specifically a robot-assisted laparoscopic extended pelvic lymph node dissection (RA-PLND) is compared to a second-look open lymph node dissection (O-PLND) among participants undergoing radical cystectomy for urothelial carcinoma of the bladder. The median yield lymph nodes illustrate the adequacy of extended pelvic lymph node dissection using a robotic-assisted technique, i.e. whether the robotic-assisted laparoscopic radical cystectomy yields a sufficient number of lymph nodes to be oncologically equivalent to the open procedure.</description>
        <time_frame>3 months including surgery and post-operative period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Robotic-assisted Laparoscopic Surgery</title>
            <description>Robotic-assisted laparoscopic extended pelvic lymph node dissection</description>
          </group>
        </group_list>
        <measure>
          <title>Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved</title>
          <description>The median yield (the lymph node count) allows for comparison of how many lymph nodes are left behind after robotic-assisted removal and are then found after a wider incision is made. Specifically a robot-assisted laparoscopic extended pelvic lymph node dissection (RA-PLND) is compared to a second-look open lymph node dissection (O-PLND) among participants undergoing radical cystectomy for urothelial carcinoma of the bladder. The median yield lymph nodes illustrate the adequacy of extended pelvic lymph node dissection using a robotic-assisted technique, i.e. whether the robotic-assisted laparoscopic radical cystectomy yields a sufficient number of lymph nodes to be oncologically equivalent to the open procedure.</description>
          <units>Nodes (Node Yield)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RA-PLND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="19" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O-PLND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Percentage Median Yield</title>
        <description>The median yield (the lymph node count) allows for comparison of how many lymph nodes are left behind after robotic-assisted removal and are then found after a wider incision is made. Specifically a robot-assisted laparoscopic extended pelvic lymph node dissection (RA-PLND) is compared to a second-look open lymph node dissection (O-PLND) among participants undergoing radical cystectomy for urothelial carcinoma of the bladder. The median yield lymph nodes illustrates the adequacy of extended pelvic lymph node dissection using a robotic-assisted technique.</description>
        <time_frame>3 months including surgery and post-operative period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Robotic-assisted Laparoscopic Surgery</title>
            <description>Robotic-assisted laparoscopic extended pelvic lymph node dissection</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Percentage Median Yield</title>
          <description>The median yield (the lymph node count) allows for comparison of how many lymph nodes are left behind after robotic-assisted removal and are then found after a wider incision is made. Specifically a robot-assisted laparoscopic extended pelvic lymph node dissection (RA-PLND) is compared to a second-look open lymph node dissection (O-PLND) among participants undergoing radical cystectomy for urothelial carcinoma of the bladder. The median yield lymph nodes illustrates the adequacy of extended pelvic lymph node dissection using a robotic-assisted technique.</description>
          <units>Percentage of Nodes (Node Yield)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RA-PLND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O-PLND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Robotic-assisted Laparoscopic Surgery</title>
          <description>Robotic-assisted laparoscopic extended pelvic lymph node dissection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bowel Leak</sub_title>
                <description>Bowel leak from the gastrointestinal anastomosis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John W. Davis, MD / Assistant Professor</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

